Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 92%
filed 2026-07-29
EX-99.1
The Trust announced an updated at-the-market (ATM) equity program to issue up to U.S.$250 million of Units, replacing a prior ATM program terminated in May 2026. This is a material dilutive issuance of equity securities in the form of Units of the Trust, authorized through an amended and restated sales agreement with multiple agents. The magnitude ($250 million) and the explicit authorization to issue new Units at market prices constitute a dilutive capital raise that would materially affect investor assessment of ownership dilution and the Trust's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 1.01
LB Pharmaceuticals entered into a Securities Purchase Agreement on July 28, 2026, to issue 3,577,560 shares of common stock and pre-funded warrants to purchase 715,513 additional shares in a private placement for approximately $150 million in gross proceeds at $34.94 per share to institutional investors under Section 4(a)(2) exemption without registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
Macquarie Infrastructure Fund sold approximately $25.4 million of unregistered limited partnership units on July 1, 2026, to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D exemptions, representing a significant capital raise and expansion of the Fund's equity base.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
Inhibikase issued a pre-funded warrant to acquire 18,030,000 shares of common stock without registration, relying on Section 3(a)(9) of the Securities Act. The warrant has a nominal $0.001 exercise price and is immediately exercisable, making it economically equivalent to a direct equity issuance. This is a classic dilutive unregistered equity transaction that would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
The filing discloses an unregistered sale of approximately 1.5 million common units for $29.7 million pursuant to subscription agreements with existing unitholders, relying on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive issuance of equity securities to accredited investors under a capital drawdown mechanism, material to investors as it represents a significant capital raise and dilution event for the fund.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
Healthcare Triangle issued 12,546,540 unregistered shares of common stock on July 28, 2026, comprising 9,718,373 shares to Teyame AI LLC entities and 2,828,167 shares to SecureKloud Technologies Ltd. counterparties, both in reliance on Section 4(a)(2) and Regulation D exemptions. This represents a substantial dilutive issuance that increased outstanding shares from approximately 2.1 million to 14.6 million—a material capital event disclosed under Item 3.02 and explicitly highlighted in the press release as strengthening the company's Nasdaq listing compliance position.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-29
The 6-K discloses entry into securities purchase agreements on July 17, 2026, for the issuance and sale of 20,000,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $200.0 million. The offering closed on July 29, 2026. This is a material registered equity issuance that dilutes existing shareholders and raises substantial capital for AI computing center development. The transaction meets the definition of dilutive_issuance under Item 3.02 equivalent disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
The Company completed an unregistered private placement of 270,000 Private Placement Units to the Sponsor at $10.00 per unit ($2.7 million aggregate) pursuant to Section 4(a)(2) exemption, concurrent with the IPO closing on July 27, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-29
Item 3.02
The Company issued 360,000 shares of common stock (Commitment Shares) as consideration under a Forbearance Letter Agreement, pursuant to Section 4(a)(2) of the Securities Act of 1933, in connection with the financing transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-07-29
Item 1.01
Onconetix entered into a Securities Purchase Agreement to issue 37,812 shares of Series F convertible preferred stock for $30.2 million, with conversion rights into common stock at $0.9767 per share, and established a committed equity facility (ELOC) allowing purchases of up to $750 million in common stock. The unregistered sale relies on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, representing a private investment in public equity (PIPE) transaction that materially dilutes existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-29
Banco Bradesco announced a capital increase of R$ 10 billion through issuance of 302.9 million new common shares and 302.0 million new preferred shares at specified prices (R$ 15.43 and R$ 17.64 respectively), offered for private subscription to existing shareholders with preemptive rights. This is a material dilutive equity issuance that would affect shareholder ownership percentages and is disclosed as a discrete corporate action resolved by the Board on July 29, 2026.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-29
Banco Bradesco announced approval of a capital increase of up to BRL 10 billion (minimum BRL 8 billion) through private subscription of new shares, with controlling shareholders committing to subscribe. The issuance of up to 604.9 million new shares (302.9 million common and 302.0 million preferred) at specified prices represents a material dilutive equity issuance. The filing explicitly discloses preemptive rights, issue pricing methodology, and allocation of proceeds to strategic investments and capitalization, all hallmarks of a dilutive equity capital raise.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-29
Item 3.02
Processa completed a concurrent private placement of approximately $200 million in Series A convertible preferred stock (163,774.679 shares at $1,221.19 per share) to institutional investors under Section 4(a)(2), with PIPE investors owning approximately 52.6% of Processa on a fully-diluted basis post-closing.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-29
EX-99.1
VivoPower announced a US$50 million private investment in public equity (PIPE) structured as convertible preference shares converting at US$7.50 per share into Class A Ordinary Shares, with participation from institutional investors and entities associated with the CEO. This is a classic dilutive issuance of convertible securities that will result in equity dilution upon conversion, material to investors assessing capital structure and ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
The filing discloses an unregistered sale of 32,110 shares of common stock to a service provider at $3.27 per share under Section 4(a)(2) of the Securities Act. This is a classic dilutive issuance—an unregistered equity sale relying on the private offering exemption. Item 3.02 is the designated disclosure item for such transactions, and the language explicitly references the exemption from registration requirements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
The filing discloses a private placement of 250,000 shares of common stock at $4.80 per share for approximately $1.2 million in aggregate proceeds under a Private Placement Agreement with Pinnacle Partners Inc., with the shares issued in reliance on Regulation S (offshore transaction). This is a classic unregistered equity issuance disclosed under both Item 1.01 (Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), which is material to investors as it represents dilution and capital raising activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
HCW Biologics entered into a Securities Purchase Agreement on July 29, 2026, to issue 618,682 units comprising 218,682 shares of common stock and 400,000 pre-funded warrants, plus common warrants contingent on stockholder approval, for approximately $1.6 million in gross proceeds. This is a classic private placement of equity securities by an emerging growth company raising capital, disclosed under Items 1.01 and 3.02, with the pre-funded warrants and common warrants representing significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-29
The filing discloses conversion notices from three directors (Casamento, Demesmin, and Goldman) electing to convert remaining outstanding principal amounts totaling approximately $466,000 under Convertible Bridge Notes into common stock. While the conversions are conditional on the stock price reaching $0.50 and insider trading compliance, this represents a material dilutive issuance of equity that will occur upon satisfaction of those conditions. The event is disclosed under Item 8.01 (Other Events) rather than Item 3.02, but the substance is a dilutive equity issuance by insiders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-29
The 6-K discloses an At The Market Offering Agreement under which Fusion Fuel Green PLC may offer and sell Class A Ordinary Shares through H.C. Wainwright & Co., LLC. The Company has already sold 256,597 shares for approximately $2.8 million and filed a prospectus supplement on July 29, 2026 relating to the offer and sale of up to $6.6 million in additional Class A Ordinary Shares. This is a dilutive equity issuance that would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
VistaOne, L.P. disclosed an unregistered sale of approximately $42.2 million in limited partnership units across multiple unit classes (B, I, R, and S) as of July 1, 2026, exempt from Securities Act registration under Section 4(a)(2), Regulation D, and Regulation S. This private placement represents a material dilutive issuance to existing unitholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-28
Item 1.01
Dynex Capital amended its at-the-market (ATM) distribution agreement on July 28, 2026, increasing the number of shares available for sale by 80,000,000 shares to a total of 301,292,973 shares, with 99,326,438 shares remaining available for issuance. This is a dilutive equity issuance under an ATM program, which is a classic signal of capital raising at small- and mid-cap issuers and would materially affect shareholder equity and voting power.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-28
EX-99.1
Instinct Bio announced entry into an indicative term sheet for a proposed equity purchase facility allowing the company to sell up to $150 million of common stock over three years at VWAP-based pricing with a discount. This is a material dilutive equity issuance arrangement that would provide discretionary capital to the company, typical of PIPE-like or ATM-style offerings used by smaller biotechnology companies to raise cash. The $150 million size and three-year duration make this material to investors assessing capital structure and dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-28
Item 1.01
Entera Bio completed a private placement of 122.96 million ordinary shares and 11.84 million pre-funded warrants for approximately $275 million in aggregate proceeds on July 28, 2026, pursuant to a Securities Purchase Agreement entered into on July 26, 2026. This unregistered equity issuance under Section 4(a)(2) of the Securities Act represents significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
CVC-PE Global Private Equity Fund, LP completed an unregistered sale of limited partnership units totaling approximately $60.2 million across multiple unit classes (R-S, R-I, C, and G) as part of a continuous private offering, exempt under Section 4(a)(2) and Regulation D. This capital-raising event dilutes existing unitholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
The filing discloses unregistered sales of Class I and Class S common stock totaling approximately $36.7 million to third-party investors, exempt from registration under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance by a BDC raising capital through private placement, material to investors assessing the company's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-28
Item 3.02
SLR HC BDC LLC disclosed an unregistered sale of approximately 200,000 units for $4.2 million to its members pursuant to a capital drawdown notice under the LLC Agreement and Subscription Agreement. The issuance is exempt from Securities Act registration under Section 4(a)(2) and Regulation D, which is characteristic of private placements to existing members. This represents a dilutive equity issuance that would be material to investors assessing the company's capital structure and ownership.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-28
C3is Inc. completed a registered offering on July 28, 2026, of 11,535,000 units (10,435,000 common units and 1,100,000 pre-funded units) with warrants, raising approximately $6.0 million in gross proceeds. The offering includes common shares, pre-funded warrants exercisable at $0.01, and Class F Warrants with reset and cashless exercise features that could result in issuance of up to 46.1 million additional common shares. This is a material dilutive equity issuance that would significantly affect investor assessment of ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
Silver Point Private Credit Fund completed an unregistered sale of 324,600 common shares for $8.7 million at $26.81 per share, executed pursuant to subscription agreements and exempt under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
North Haven Private Income Fund A LLC completed an unregistered sale of approximately 19,523 Class I units for $0.4 million, relying on Section 4(a)(2) and Regulation D exemptions with accredited investor representations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
West Bay BDC LLC is conducting an unregistered sale of approximately 1.6 million common units for $27.8 million to existing investors pursuant to subscription agreements and capital drawdown notices. The sale is exempt under Section 4(a)(2) and Regulation D, with purchasers required to be accredited investors or non-U.S. persons. This is a classic dilutive issuance of equity securities to raise capital, material to investors assessing the company's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
North Haven Private Income Fund LLC completed an unregistered sale of approximately 122,704 Class S units for $2.20 million, relying on Section 4(a)(2) and Regulation D exemptions with accredited investor representations.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-28
EX-99.1
Enlivex announced a $400 million private placement of ordinary shares at $5.00–$6.00 per share to a single institutional investor, with an additional $400 million call option exercisable over 36 months on identical terms. This is a material unregistered equity issuance (private placement) that will significantly dilute existing shareholders and raise substantial capital. The filing explicitly notes that closing is subject to shareholder approval under Nasdaq Listing Rule 5635, confirming the dilutive nature and materiality of the transaction.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-28
EX-99.1
This is a subscription agreement for an unregistered sale of ordinary shares by Star Fashion Culture Holdings Ltd to Xingji Zhangpingting Limited pursuant to Regulation S, at $1.30 per share. The agreement explicitly states the shares are "restricted securities" and the offering is structured as an offshore transaction to non-U.S. persons to avoid Securities Act registration. This is a classic private placement / dilutive issuance of equity securities outside the registered public market, material to investors as it increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-28
EX-99.1
The exhibit announces the closing of a registered direct offering of 1,281,646 ADSs (representing 384,493,800 ordinary shares) at US$3.16 per ADS, raising approximately US$4.1 million in gross proceeds. The offering also includes concurrent private placement of unregistered warrants to purchase additional ADSs, plus a separate Australian private placement and Share Purchase Plan. This is a material dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital through registered and unregistered securities offerings.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Enlivex entered into a Securities Purchase Agreement on July 27, 2026, to issue $400 million of ordinary shares and pre-funded warrants in a private placement to an institutional investor (Rain Foundation), with an optional put right for an additional $400 million. This is an unregistered equity issuance under Section 4(a)(2) / Regulation D, structured as a PIPE-like transaction with cryptocurrency payment options and immediate warrant exercisability at $0.001 per share. The scale ($400M+ potential) and dilutive warrant structure (24.9% beneficial ownership cap, no expiration) represent material capital raising and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-28
Item 1.01
LiveOne agreed to issue 70,000 shares of common stock at $7.50 per share to Music Story SAS as payment for licensing fees and prepayment under an extended license agreement. The shares are issued pursuant to an effective S-3 registration statement with no cash proceeds to the company, representing a dilutive equity issuance that would materially affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-28
EX-99.1
This press release announces a registered direct offering of 20 million Class A Ordinary Shares at $0.20 per share (or pre-funded warrants), generating approximately $4 million in gross proceeds. The offering represents a significant dilutive equity issuance to institutional investors under a shelf registration statement. This is a material capital-raising event that would affect a reasonable investor's assessment of share dilution and the company's financial position.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-28
EX-99.1
This exhibit is a Securities Purchase Agreement for the issuance of 15,000,000 Class A ordinary shares at $0.276 per share to non-US persons under Regulation S and Section 4(a)(2) exemptions. The agreement documents an unregistered private placement of equity securities, which is a dilutive issuance material to investors assessing the registrant's capital structure and ownership dilution.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Ridgetech entered into a sales agreement on July 28, 2026 with Pacific Century Securities, LLC to offer and sell ordinary shares with an aggregate offering price of $184.7 million under an at-the-market (ATM) offering program. This is a dilutive equity issuance that replaces a prior ATM program (terminated July 11, 2026 with AC Sunshine Securities). The magnitude ($184.7M) and structure (unregistered continuous offering) are material to investors assessing capital structure and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
Market Technology Acquisition Corp completed an unregistered private placement of 712,500 units (comprising Class A Ordinary Shares and redeemable Warrants) to the Sponsor and BTIG, LLC for $7.125 million, simultaneously with the IPO closing, exempted from registration under Section 4(a)(2) of the Securities Act of 1933.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-28
Item 3.02
The Company completed an unregistered sale of warrants (equity securities) pursuant to Section 4(a)(2) of the Securities Act to an accredited investor (the Subordinated Lender), diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
The filing discloses an unregistered private placement under Item 3.02, with the Company issuing 4,340 shares of Series B Preferred Stock and 284,156 Warrants for approximately $3.472 million in cash on July 27, 2026. This is a dilutive equity issuance relying on Section 4(a)(2) and Regulation D exemptions, representing the second closing under a Securities Purchase Agreement. The issuance of convertible preferred stock and warrants is material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
The filing discloses an unregistered sale of 11,470,000 shares of Common Stock to Yorkville Advisors (YA II PN, Ltd.) between May 14 and July 24, 2026, pursuant to a Standby Equity Purchase Agreement (SEPA), generating approximately $3.6M in gross proceeds. The shares were issued under Section 4(a)(2) and Regulation D Rule 506(b) exemptions, and the transaction materially dilutes existing shareholders while providing the company with capital. This is a classic dilutive issuance disclosure under Item 3.02.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-28
EX-99.2
Anfield Energy closed a non-brokered private placement on January 12, 2026, issuing 1,345,292 common shares at US$4.46 per share for US$6,000,000 and 896,861 subscription receipts to insider Uranium Energy for US$4,000,000, totaling US$10,000,000 in gross proceeds under the Listed Issuer Financing Exemption. The transaction includes insider participation and materially affects the company's ownership structure and capital position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-28
Item 8.01
Welltower entered into an at-the-market (ATM) equity distribution agreement on July 28, 2026, authorizing the issuance and sale of up to $7.5 billion in common stock through multiple sales agents. The filing also discloses a resale prospectus supplement for 261,753 shares issued as consideration for a lease amendment. ATM offerings represent a dilutive issuance of equity securities that would materially affect investor assessment of share dilution and capital structure, fitting the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-28
Item 3.02
Kinetic Seas conducted an unregistered sale of equity securities relying on Section 4(a)(2) and Rule 506 exemptions as part of the Securities Purchase Agreement, representing a material private placement to a private investor.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
Carlyle Credit Solutions completed an unregistered sale of 2,904,955 shares of Class I common stock for $52.3 million in aggregate consideration under Section 4(a)(2) and Regulation D exemptions, increasing outstanding shares from approximately 95.5 million to 98.4 million.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-28
Item 8.01
The company disclosed an ongoing 'New Continuous Offering' of unregistered Class I Common Stock shares on a continuous basis, with 67.4 million shares issued for $1.3 billion in total consideration and stated intent to continue selling shares monthly.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-28
Item 3.02
Core Scientific issued a warrant to AMD to purchase up to 30 million shares of common stock at $23.47 per share, with approximately 6.5 million shares vesting immediately upon execution of leases on July 27, 2026, in reliance on Section 4(a)(2) of the Securities Act.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-27
Item 3.02
5C Lending Partners Corp. completed an unregistered private placement of approximately 3.7 million shares of common stock for $90 million in gross proceeds on July 24, 2026, pursuant to subscription agreements with investors, exempt from Securities Act registration under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →